Jacob Vogan, Ph.D. CSO / Founder Jacob Vogan, Ph.D., is the Chief Scientific Officer and co-founder of CB Therapeutics, a biotechnology company revolutionizing the production of psychedelic medicines and other therapeutic compounds through synthetic biology. Dr. Vogan has pioneered fermentation-based methods that transform psychedelic compound production through scalable, high purity, and environmentally sustainable processes. Dr. Vogan completed his Ph.D. and postdoctoral work at UC Berkeley, specializing in cellular aging and protein engineering. He co-founded CB Therapeutics with his college friend, Sher Butt (CEO), in 2016 to tackle the inefficiencies of traditional compound production. Under his leadership, the company developed proprietary platforms that enable the biosynthesis of tryptamines, ergolines, monoterpene indole alkaloids, and other psychedelic molecules using engineered yeast and simple sugar feedstocks. This innovation minimizes ecological impact while ensuring consistent quality and yield for clinical and therapeutic applications. As CSO, Dr. Vogan oversees a multidisciplinary team and pilot biomanufacturing facility, driving the development of novel biosynthetic pathways and fermentation optimization. His work extends beyond producing established compounds to creating new derivatives and precursors that hold promise for enhanced mental health treatments. Through partnerships like TryptageniX with atai Life Sciences, Dr. Vogan is advancing psychedelic-assisted therapies for depression, PTSD, and anxiety, addressing the critical need for sustainable and reliable supply chains. His mission is to make these transformative medicines accessible through scalable, ethical, and regulated production methods, ensuring a brighter future for patients worldwide.

‍